Haemonetics Profit Margin

Haemonetics (HAE) currently reports a profit margin of 7.29% as of March 2026. That compares with 12.32% in the prior-year period — down 40.8% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Haemonetics's profit margin history and peer comparisons.

Haemonetics's profit margin decreased from 12.32% to 7.29% — a 40.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Haemonetics's profit margin of 7.29% is lower than the Healthcare sector average of 15.58%. That is roughly 53.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Haemonetics's current 7.29% should be judged against Healthcare norms (sector average: 15.58%) and against HAE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 7.29%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Haemonetics, and consider following HAE for alerts when major investors trade the stock.